Acquisition

Valo and Montai merge to build human-evidence drug discovery platform

What's the deal? Valo Health has merged with Montai Therapeutics to form a single drug discovery company built on what the firms call "human evidence." The combined business keeps the Valo Health name and is led by Brian Alexander, Valo's chief executive officer and a CEO-partner at Flagship Pioneering. Terms were not disclosed.

What each side brings: Valo contributes its AI-enabled human causal biology and closed-loop chemistry platforms, which design molecules from trillions of starting points. Montai adds its chemistry platform and a clinical-stage immunology and inflammation (I&I) pipeline.

What's the endgame? The merged company will advance wholly owned I&I programmes while continuing partnered work. Its lead asset is MTAI-1025, an oral NRF2 agonist now in a Phase 1 trial for ulcerative colitis, alongside an oral STAT6 inhibitor for atopic dermatitis and other type 2 inflammatory diseases.

Why now? Valo lost its in-licensed clinical assets in 2024, when OPL-0401 missed its Phase 2 endpoints, and has since leaned on partnerships with Novo Nordisk and Merck KGaADealroom has a profile for this one. Try Dealroom →. Montai's pipeline restores near-term clinical assets to the combined portfolio.

"Valo and Montai were founded on the belief that human evidence should guide every step of drug discovery," Alexander said. He added that the deal offers "a clear path to its next stage of growth."

Why it integrates easily: Both companies were founded within the Flagship Pioneering ecosystem and share a scientific approach, which the firms say should let them combine without disrupting programmes. Margo Georgiadis, Montai's co-founder and chief executive officer, will stay on as an adviser through the transition.

"We've proven the platform works, successfully advancing multiple differentiated development candidates for clinically validated targets historically intractable for small molecules," Georgiadis said.

The signal: The merger fits a push to combine AI drug-discovery platforms rather than keep standalone software running, echoing Flagship's October launch of EtceleraDealroom has a profile for this one. Try Dealroom → from three of its biotech platforms. By pairing a discovery engine with a clinical pipeline, Valo gains assets with nearer-term potential — though success will hinge on integration and trial progress, not the platform claim alone.

Read more: finance.yahoo.com

Image credit: Generated with Gemini

More top stories